Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PDSB

PDS Biotechnology Corporation

Apr 19 • 10:28AM ET

2.76

Dollar change -0.14
Percentage change -5.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC RYLD VTWG QQQS BTEC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.39	Insider Own	4.89%	Shs Outstand	36.68M	Perf Week	-13.64%
Market Cap	101.05M	Forward P/E	-	EPS next Y	-1.61	Insider Trans	0.00%	Shs Float	34.89M	Perf Month	-42.72%
Income	-42.94M	PEG	-	EPS next Q	-0.37	Inst Own	22.52%	Short Float	17.63%	Perf Quarter	-38.78%
Sales	0.00M	P/S	-	EPS this Y	-6.83%	Inst Trans	-2.52%	Short Ratio	6.63	Perf Half Y	-36.52%
Book/sh	0.79	P/B	3.49	EPS next Y	-8.69%	ROA	-62.97%	Short Interest	6.15M	Perf Year	-58.26%
Cash/sh	1.54	P/C	1.79	EPS next 5Y	-	ROE	-122.46%	52W Range	2.68 - 10.27	Perf YTD	-44.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	42.97%	ROI	-93.84%	52W High	-73.17%	Beta	1.79
Dividend TTM	-	Quick Ratio	4.33	Sales past 5Y	0.00%	Gross Margin	-	52W Low	2.80%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	4.33	EPS Y/Y TTM	4.64%	Oper. Margin	0.00%	RSI (14)	29.05	Volatility	10.08% 9.17%
Employees	25	Debt/Eq	0.91	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.40
Option/Short	Yes / Yes	LT Debt/Eq	0.75	EPS Q/Q	48.28%	Payout	-	Rel Volume	1.08	Prev Close	2.90
Sales Surprise	-	EPS Surprise	20.20%	Sales Q/Q	-	Earnings	Mar 27 BMO	Avg Volume	928.03K	Price	2.76
SMA20	-23.46%	SMA50	-41.22%	SMA200	-45.60%	Trades		Volume	191,558	Change	-5.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-01-22	Initiated	B. Riley Securities	Buy	$10
Jun-28-21	Initiated	Cantor Fitzgerald	Overweight	$25
Nov-10-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6
May-27-20	Initiated	Alliance Global Partners	Buy	$4
Mar-09-20	Initiated	Noble Capital Markets	Outperform	$5.45
Oct-24-19	Initiated	Chardan Capital Markets	Buy	$10

Mar-28-24 10:24AM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-27-24 11:33PM	Q4 2023 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents) -14.06%
11:52AM	PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023 (InvestorPlace)
08:51AM	PDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy Update (GuruFocus.com)
07:30AM	PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
08:00AM	Loading…
Mar-20-24 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results (GlobeNewswire)
Mar-13-24 10:55AM	The 3 Most Undervalued Biotech Stocks to Buy in March 2024 (InvestorPlace)
08:00AM	PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune (GlobeNewswire)
Jan-22-24 04:45PM	PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer (GlobeNewswire)
Jan-16-24 08:00AM	PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire) -5.44%
Jan-02-24 12:00PM	All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy (Zacks)
Dec-04-23 04:50PM	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-23 07:30AM	PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer (GlobeNewswire) -9.66%
Nov-15-23 01:03PM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 12:19PM	PDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in ... (GuruFocus.com) +18.55%
07:42AM	Loading…
07:42AM	PDS Biotechnology: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-23 08:00AM	PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Na ve Patients at 36 Months (GlobeNewswire) +5.36%
Nov-07-23 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 08:00AM	PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO (GlobeNewswire)
Oct-11-23 08:00AM	PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer (GlobeNewswire)
Oct-03-23 07:00AM	PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Na ve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA (pembrolizumab) (GlobeNewswire) -14.47%
Oct-02-23 08:00AM	PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA) (GlobeNewswire) -6.93%
Sep-26-23 08:00AM	PDS Biotech to Present at the LD Micro Main Event XVI (GlobeNewswire)
Sep-25-23 08:00AM	PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 (GlobeNewswire)
Sep-20-23 04:05PM	PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
08:00AM	PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies (GlobeNewswire)
Sep-13-23 08:00AM	PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023 (GlobeNewswire)
Sep-06-23 04:05PM	PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:00AM	PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference (GlobeNewswire)
11:32AM	Loading…
Aug-29-23 11:32AM	PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why (Zacks) -6.56%
Aug-16-23 08:00AM	PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting (GlobeNewswire) +5.95%
Aug-14-23 11:42PM	Q2 2023 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents) +9.90%
07:37AM	PDS Biotechnology: Q2 Earnings Snapshot (AP Finance)
07:30AM	PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial (GlobeNewswire)
Aug-07-23 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-02-23 08:00AM	PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-25-23 08:00AM	PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023 (GlobeNewswire)
Jul-17-23 08:00AM	PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023 (GlobeNewswire) +7.60%
Jul-11-23 08:00AM	PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301 (GlobeNewswire)
Jun-30-23 04:05PM	PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-20-23 08:00AM	PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 (GlobeNewswire)
Jun-14-23 08:00AM	PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer (GlobeNewswire) -9.88%
Jun-05-23 02:52PM	PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET (GlobeNewswire) -30.68%
May-25-23 05:00PM	PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients (GlobeNewswire) -6.99%
May-18-23 08:00AM	PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer (GlobeNewswire)
May-17-23 01:54PM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 09:46PM	Q1 2023 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents) +7.44%
07:40AM	PDS Biotechnology: Q1 Earnings Snapshot (AP Finance)
07:30AM	PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 08:00AM	PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients (GlobeNewswire)
Apr-24-23 08:00AM	PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program (GlobeNewswire)
Apr-12-23 08:00AM	PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023 (GlobeNewswire)
Apr-03-23 08:00AM	PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023 (GlobeNewswire)
Mar-30-23 08:28AM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2022 Earnings Call Transcript (Insider Monkey)
08:00AM	PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023 (GlobeNewswire)
Mar-29-23 07:30AM	PDS Biotech to Participate in Cantors Future of Oncology Virtual Symposium (GlobeNewswire)
Mar-28-23 07:30AM	PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Mar-16-23 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results (GlobeNewswire)
Mar-07-23 08:00AM	PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference (GlobeNewswire)
Mar-01-23 08:00AM	PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal (GlobeNewswire)
Feb-27-23 08:00AM	PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor (GlobeNewswire)
Feb-16-23 08:00AM	PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune (GlobeNewswire)
Feb-15-23 09:00AM	3 Deeply Undervalued Stocks That Could Double Your Money (Motley Fool)
Feb-08-23 04:00PM	PDS Biotech Announces Publication of Preclinical Infectimune Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses (GlobeNewswire)
Feb-06-23 08:00AM	PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress (GlobeNewswire)
Jan-26-23 08:00AM	PDS Biotech Announces Participation in the Channelchek Takeaway Series (GlobeNewswire)
Jan-13-23 08:00AM	PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire)
Jan-03-23 11:13AM	PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment (Benzinga) -19.55%
07:00AM	PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany (GlobeNewswire)
Dec-29-22 10:29AM	PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study (Zacks) +13.33%
Dec-28-22 10:39AM	12 Best Biotech Stocks to Buy Under $10 (Insider Monkey) +23.78%
08:00AM	PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months (GlobeNewswire)
Dec-15-22 08:00AM	PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer (GlobeNewswire)
Dec-05-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Frank Bedu-Addo, CEO PDS Biotechnology Corporation (ACCESSWIRE) -7.67%
Nov-21-22 08:00AM	PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress (GlobeNewswire)
Nov-14-22 07:30AM	PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +26.07%
07:00AM	PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial (GlobeNewswire)
Nov-07-22 08:00AM	PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022) (GlobeNewswire) +6.63%
Oct-31-22 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-28-22 01:23PM	11 Popular Penny Stocks On Robinhood (Insider Monkey) +5.28%
Oct-27-22 08:00AM	PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable (GlobeNewswire)
Oct-25-22 08:00AM	PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference (GlobeNewswire) +10.39%
Oct-20-22 09:33AM	2 Strong Buy Penny Stocks That Could Rally to $14 (Or More) (TipRanks) +14.11%
Oct-19-22 08:00AM	PDS Biotech to Present at the LD Micro Main Event XV (GlobeNewswire)
Oct-17-22 08:00AM	PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy (GlobeNewswire)
Oct-14-22 11:00AM	2 New Oncology Focused Small-Cap Biotechs to Keep an Eye On (TheStreet.com)
Oct-12-22 08:00AM	PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022 (GlobeNewswire)
Oct-11-22 08:00AM	PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers (GlobeNewswire) +16.42%
Oct-07-22 04:01PM	PDS Biotech Reports An Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.98%
Oct-05-22 08:00AM	PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022 (GlobeNewswire)
Oct-03-22 08:00AM	PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA® (GlobeNewswire) +10.44%
Sep-23-22 04:05PM	PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-22-22 08:00AM	PDS Biotech to Participate at Cantor Fitzgeralds Oncology & HemOnc Conference (GlobeNewswire)
Sep-21-22 08:00AM	PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers (GlobeNewswire)
Sep-06-22 08:00AM	PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-24-22 04:01PM	PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance (GlobeNewswire)
Aug-11-22 09:55AM	How Much Upside is Left in PDS Biotechnology (PDSB)? Wall Street Analysts Think 265% (Zacks) -6.21%

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PDSB

PDS Biotechnology Corporation

Upgrade your FINVIZ experience